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Abstract 
Background: Streptococcus pneumoniae is a common cause of child death. However, the economic burden of pneu-
mococcal disease in low-income countries is poorly described. We aimed to estimate from a societal perspective, the 
costs incurred by health providers and families of children with pneumococcal diseases.
Methods: We recruited children less than 5 years of age with outpatient pneumonia, inpatient pneumonia, pneu-
mococcal sepsis and bacterial meningitis at facilities in rural and urban Gambia. We collected provider costs, out of 
pocket costs and productivity loss for the families of children. For each disease diagnostic category, costs were col-
lected before, during, and for 1 week after discharge from hospital or outpatient visit.
Results: A total of 340 children were enrolled; 100 outpatient pneumonia, 175 inpatient pneumonia 36 pneumococ-
cal sepsis, and 29 bacterial meningitis cases. The mean provider costs per patient for treating outpatient pneumonia, 
inpatient pneumonia, pneumococcal sepsis and meningitis were US$8, US$64, US$87 and US$124 respectively and 
the mean out of pocket costs per patient were US$6, US$31, US$44 and US$34 respectively. The economic burden 
of outpatient pneumonia, inpatient pneumonia, pneumococcal sepsis and meningitis increased to US$15, US$109, 
US$144 and US$170 respectively when family members’ time loss from work was taken into account.
Conclusion: The economic burden of pneumococcal disease in The Gambia is substantial, costs to families was 
approximately one-third to a half of the provider costs, and accounted for up to 30 % of total societal costs. The intro-
duction of pneumococcal conjugate vaccine has the potential to significantly reduce this economic burden in this 
society.
© 2016 Usuf et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
There was an estimated 826,000 deaths due to pneumo-
coccal diseases. In the year 2000, representing more than 
11  % of all childhood deaths with 90  % of deaths from 
pneumococcal pneumonia occurring in Africa [1]. In 
2013 pneumonia remains a leading cause of death con-
tributing 15  % of the total global child deaths [2]. The 
pneumococcus is the most common cause of pneumonia, 
sepsis, and meningitis [3]. In addition to high case fatality 
rates, survivors of pneumococcal meningitis often expe-
rience disability such as cognitive impairment, seizures 
and deafness [4, 5].
In spite of the extensive disease burden, data describ-
ing the economic burden of pneumococcal disease in 
sub-Saharan Africa are limited. A study in Kenya esti-
mated the treatment cost for episodes of pneumonia in 
children to vary from US$54 to US$99 in regional and 
district hospitals and up to US$177 in the national hos-
pital. For meningitis, the estimated costs were higher, 
US$189 to US$201 and up to US$284 in the national hos-
pital [6]. Another study in Zambia found the treatment 
costs of outpatient and inpatient pneumonia to be US$48 
and US$215 respectively [7]. During a clinical trial of a 
pneumococcal conjugate vaccine (PCV) in The Gambia, 
the average treatment cost of pneumococcal illness was 
estimated at US$191 [8].
Most studies of the economic burden of disease or 
vaccine cost-effectiveness do not collect primary data 
on costs but instead rely upon other sources such as 
estimates from neighbouring countries often with a 
number assumptions [9, 10] or the ‘WHO-CHOICE’ 
(choosing interventions that are cost-effective) 
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database of cost estimates for hospital care [11]. How-
ever, several studies have demonstrated that the WHO-
CHOICE cost estimates generally underestimate the 
true cost when compared to micro costing methods 
[11, 12].
Effective PCVs are now available and with the help of 
Gavi, the Vaccine Alliance, these vaccines are becom-
ing part of routine immunisation in many develop-
ing countries [13]. In 2009, The Gambia was one of the 
first countries in Africa to introduce PCV. Pneumo-
coccal vaccination is associated with high investment 
costs. An assessment of the likely economic benefits of 
PCV is essential in settings with limited resources [14]. 
Determining the cost-effectiveness of different vaccines 
will assume greater importance as immunisation pro-
grammes add more expensive vaccines such as PCV and 
rotavirus vaccine, to the less expensive, traditional vac-
cines such as measles, oral polio and BCG.
A study to determine the impact of PCV in The Gam-
bia has been underway since 2008 [15]. Our economic 
evaluation has already estimated the cost of introduc-
ing PCV into the national Expanded Programme of 
Immunisation (EPI) [14]. In order to provide accurate 
estimates of the economic burden of pneumococcal 
disease we used micro-costing methods with empiric, 
local, data, including costs to both the health care pro-
vider and families. We also conducted sensitivity analy-
ses and we provide a national estimate of the economic 
burden of disease. These findings provide critical inputs 
to evaluate the overall cost-effectiveness of introducing 
PCV.
Methods
Setting
The study was undertaken in 2011 and 2012 at two sites, 
Basse Health Centre (Basse), in a rural town in upper 
river region (URR), The Gambia and Royal Victoria 
Teaching Hospital (RVTH) recently renamed Edward 
Francis Small Teaching Hospital in Banjul, the capital 
city. The health centre at Basse serves as a referral centre 
for all minor health centres in URR and RVTH serves as 
the main tertiary hospital for all regions.
Treatment of children aged under 14  years in The 
Gambia is provided free of charge. Case management of 
pneumonia follows WHO’s Integrated Management of 
Childhood Illness strategy. Even though the costs directly 
related to treatment at health facilities are covered by 
the government, families incur out-of-pocket expenses 
and loss of income before presentation to hospital, while 
taking care of a sick child at hospital and after discharge. 
Additionally, sequelae following pneumococcal meningi-
tis are common and result in substantial economic bur-
den to families.
Participants
Children were potentially eligible for the study if they 
were aged less than 5 years and attended Basse or RVTH. 
Patients attending RVTH were assessed for eligibility by 
study staff on a daily basis between 9am and 2pm. Chil-
dren were given treatment at the outpatient department 
(OPD) or admitted to the ward according to the discre-
tion of the attending clinician. Patients in Basse were 
enrolled in a surveillance project to monitor individu-
als with pneumonia, sepsis and meningitis [15]. Surveil-
lance staff used standardised criteria to screen and refer 
patients with possible pneumonia, sepsis, or meningitis 
to surveillance clinicians who then assessed and investi-
gated children according to standard criteria and admit-
ted patients according to their clinical judgement. We 
enrolled the caregivers of children in four diagnostic 
categories: (1) a clinician’s diagnosis of clinical pneumo-
nia treated as an outpatient, (2) a clinician’s diagnosis of 
clinical pneumonia admitted to the ward, (3) an illness 
in which Streptococcus pneumoniae was isolated from 
blood, and (4) an illness in which pathogenic bacteria was 
isolated from cerebrospinal fluid.
Data collection
After confirmation of eligibility and informed consent, 
study staff interviewed the child’s caregiver. For hospital-
ised patients, data were collected for the day of admission 
and any days of illness prior to this first interview. Subse-
quently, caregivers were interviewed on a daily basis to 
obtain retrospective data during the previous 24 h, until 
the day of discharge. Caregivers of children treated at the 
OPD were interviewed on the day of presentation and 
after the discharge of patients. Staff conducted a home 
visit 7  days after discharge or outpatient visit and col-
lected data on costs incurred during the days following 
discharge/visit until the day of the home visit. All data 
were recorded on standardised questionnaires.
We collected data in order to determine costs per case. 
Data included staff cost, clinical consumables, drugs 
consumed by each patient, diagnostic tests, the number 
of days on intravenous fluid, number of days on oxygen 
therapy, and the length of hospital stay. We used the unit 
costs of each medication provided by the national phar-
maceutical service which procures and distributes drugs 
to all government facilities (Additional file  1: Table S1). 
We used either the dose-specific cost or the full cost, 
depending on whether a drug vial could be used for 
additional patients or had to be discarded once it was 
opened and partially used. For blood transfusion we used 
the reported cost of providing one unit of blood from 
the national blood transfusion service, US$9.02 (per-
sonal communication, Jaye P. 2011). We estimated the 
cost of oxygen by using the purchase price of an oxygen 
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concentrator, its expected shelf life and the ratio of oxy-
gen cost when provided by concentrator compared to 
oxygen cylinders as determine by Howie et al. [16]. The 
average cost of 1 day of oxygen therapy was estimated to 
be US$1.95. The costs of diagnostic tests were derived 
from the Medical Research Council, The Gambia Unit 
(MRC). Since the RVTH user charges for older children 
and adults are heavily subsidised by the government, we 
used the MRC estimates which take into account all rel-
evant cost components. We collected costs from private 
laboratories and compared these with the MRC labora-
tory costs (Additional file 1: TableS2) for inputs in a sce-
nario analysis.
Costs per hospital bed day
The resources used at both study sites are summarised 
in Additional file 1: Table S3. Bed occupancy, the average 
proportion of beds that are occupied at any one time, was 
calculated as the total number of admissions multiplied 
by the average duration of admission in days, divided by 
365. Dividing this average number of patients per day by 
the number of beds gives the bed occupancy rate. We 
used the government salary scale and lists of facility per-
sonnel and their grades to calculate the daily cost of per-
sonnel in each facility. We excluded the cost of buildings, 
maintenance, cleaning and utilities as these data were not 
readily available. Market costs of locally purchased food-
stuffs and the weekly menu of meals were used to esti-
mate the daily cost of food provided by the hospital and 
local prices and the daily volume of materials consumed 
were used to estimate the daily cost of laundry.
Family out‑of‑pocket costs
Out-of-pocket costs to caregivers and other family mem-
bers were estimated for three periods, before and during 
hospitalisation, and for 1 week after discharge. Data col-
lected included the following: costs of diagnostic tests, 
consultations, drugs and transportation before presen-
tation to the facility, food consumed during the hospi-
tal stay, its source and the actual cost or an estimate if it 
was not purchased, the source of money which was used 
by the caregiver to pay for the costs and total house-
hold expenditure. We also recorded the costs of burial at 
RVTH. Additionally, we estimated time loss by caregiv-
ers and visitors due to travelling between home and facil-
ity, and while the patient received treatment at the health 
facility,
Costs associated with bacterial meningitis sequelae
Children aged 5  years or less with confirmed bacterial 
meningitis were recruited separately to estimate the costs 
associated with sequelae following pneumococcal men-
ingitis. In the coastal area, these children were recruited 
retrospectively from patients who were enrolled in an 
MRC meningitis surveillance project between 2008 and 
2010. These children were enrolled within 24  months 
after the illness. Staff enquired about the child at the 
given address and sought informed consent from the car-
egiver if the child was identified. Children in Basse with 
meningitis were enrolled prospectively as part of the sur-
veillance study but caregivers were only approached for 
economic burden of meningitis sequelae data 6  months 
after the acute illness.
For both retrospective and prospective cases, we 
only recorded data up to 6  months post discharge. We 
recorded the duration of the admission and the esti-
mated amount of money spent before, during and for 
1  week after discharge from hospital. We also recorded 
the degree to which the child was able, or unable, to per-
form normal activities and treatment costs during the 
period from 1 week and up to 6 months after discharge. 
The level of care provided and the relationship with the 
caregiver was recorded. Payments for someone to take 
care of the child or loss of income for those providing 
care were estimated based on their likely income if they 
were employed.
Health facility surveys
To assess the generalisability of data collected at RVTH 
and Basse to other health facilities in the country, we 
interviewed the nurse in charge at RVTH, Basse, one 
other hospital from the remaining five regional hospitals 
and at four out of approximately 50 other public health 
centres spread across the country. Selection of health 
facilities used a purposeful approach according to num-
ber of government facilities of different sizes in rural and 
urban regions. We collected data on standard treatment 
protocols, available diagnostic tests, staffing levels, provi-
sion of food, and numbers of patients admitted in 2010 
with pneumonia, sepsis and meningitis.
Ethics
All caregivers who participated provided written 
informed consent. Caregivers read the project informa-
tion sheet or staff read the sheet in a language that the 
carer understood. After consent the caregiver signed 
a form, or provided their thumb print. Nurses at the 
surveyed health facilities gave verbal consent after 
reading the information sheet provided. The Gambia 
Government/MRC Joint Institutional Ethics Commit-
tee approved the study (SCC 1211), as did the PATH 
Research Ethics Committee (HS 560).
Analysis
We aimed to collect cost data from a sample of 100 
pneumonia cases at each centre, 50 inpatient and 50 
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outpatient. Assuming a mean cost of U$100 per case 
with a standard deviation of US$33 [6], enrolment of 50 
patients in each category would provide an estimate with 
precision of ± US$6.5. Given the limited number of sep-
sis and meningitis cases, the sample size was based on 
the number of cases identified.
All costs were presented in total, mean, median, and 
inter quartile range (IQR) by facility and by diagnosis. To 
determine the total provider costs, the estimated average 
treatment cost for each diagnostic category was added 
to the estimated bed day cost multiplied by the average 
duration of admission for each diagnostic category. Esti-
mation of costs to the caregiver and family associated 
with sequelae following bacterial meningitis was calcu-
lated in a similar manner. We placed a value on the time 
loss based on the daily wage or how much the caregiver 
would pay for the work to be carried out, whichever was 
provided in the questionnaire, both options were avail-
able [17]. The total societal cost was a summation of the 
costs to the provider, costs borne by caregivers and fami-
lies for each diagnostic category and the productivity loss 
of family members. All costs were estimated in US$ dol-
lars using the average exchange rate for the year 2010.
Sensitivity analysis
Two different scenarios were analysed. One scenario 
assumed lower levels of access to diagnostic tests. Given 
the use of X-ray and microbiology investigations in Basse 
was greater than at the RVTH and other facilities, a sen-
sitivity analysis was conducted based on utilization of 
these investigations at RVTH. In a second scenario, we 
compared costs for diagnostic test from private laborato-
ries to costs at the MRC which were used in the base case 
analysis.
Results
Characteristics of patients
A total of 340 patients were recruited, 197 (57.9 %) from 
Basse and 143 (42.1  %) from RVTH. There were more 
males at both sites. Overall 57.4  % of the children were 
male. The median age (IQR) in months was 9 (4–18) 
and 10 (4–24) in Basse and RVTH respectively. The 
age distribution was not different between the two sites 
(p value =  0.41). Table  1 shows the number of patients 
recruited in each diagnostic category, from each facility.
The average inpatient stay was 5.8  days; 4.6  days in 
Basse and 7.6  days at RVTH. The maximum stay was 
35  days. Thirty-six (10.6  %) children died and one 
absconded from hospital. Ten (4.2  %) children died on 
the same day they were admitted. The children who 
died had an average length of stay of 3.9 days compared 
to 6.1  days for children who survived (p value  =  0.02). 
Deaths were more common among the meningitis cases 
16/29 (55.2 %) compared to sepsis (10/36) and pneumo-
nia (10/175) cases (p value < 0.001). No patient who was 
treated for pneumonia as an outpatient died during the 
study period.
Characteristics of caregivers and households
The mother was the caregiver for 90.6 % of cases and the 
father for 6.8  %. On average, there were 12 (IQR 6–15) 
adults and 15 (IQR 7–20) children aged under 18  years 
per household in Basse and 5 (IQR 3–7) adults and 6 
(IQR 3–7) children per household in urban areas. The 
average daily household expenses were greater in Basse 
at US$9.05, (median, IQR US$7.35, 3.7–11.0) than RVTH 
at US$5.40, (median, IQR US$3.70, 2.7–5.9). The per cap-
ita expense per day based on the size of the household 
however was US$ 0.49 and US$ 0.33 at Basse and RVTH 
respectively.
Thirteen percent of households (8 % in rural area and 
18.8  % in urban area) reported that there were one or 
more days in the previous month when there was no 
food in the house. The source of income to cover medi-
cal expenses was exclusively from current income in 
25.7 % of households, savings 21.0 %, cutting down other 
expenses 10.1 %, and borrowing or donations from rela-
tives and friends 6.2 and 18.5  % respectively. Selling 
assets was not common (1.1 %) and 17.4 % had a combi-
nation of financing strategies.
Provider costs
The paediatric bed occupancy rate at RVTH and Basse 
were 0.88 and 0.95 respectively. Aggregating the esti-
mated costs per patient day for food, laundry, and per-
sonnel, the estimated cost per paediatric patient day at 
Basse was US$5.29 and US$4.37 in RVTH.
The distributions of costs were generally right-skewed. 
The average total provider treatment cost for outpatient 
pneumonia, inpatient pneumonia, pneumococcal sep-
sis and bacterial meningitis were US$5.50, US$60.90, 
US$90.90 and US$131.00 in Basse and US$9.80, 
US$67.90, US$51.60 and US$104.20 at RVTH respec-
tively per patient (Table 2). Fifty-three children (15.6 %) 
received three or more antibiotics during the treatment.
Table 1 Number of  children recruited and  the number 
that died in each diagnostic category
Diagnosis Basse
N (%)
RVTH
N (%)
Total
N (%)
Deaths
N (%)
Outpatient pneumonia 50 (25.4) 50 (35.0) 100 (29.4) 0 (0.0)
Inpatient pneumonia 94 (47.7) 81 (56.6) 175 (51.5) 10 (5.7)
Pneumococcal sepsis 32 (16.2) 4 (2.8) 36 (10.6) 10 (27.8)
Bacterial meningitis 21 (10.7) 8 (5.6) 29 (8.5) 16 (55.2)
Total 197 (100.0) 143 (100.0) 340 (100) 36 (10.6)
Page 5 of 10Usuf et al. Cost Eff Resour Alloc  (2016) 14:4 
Family out‑of‑pocket costs
Table 3 summarises the mean out-of-pocket costs by dis-
ease category. Half (174/340) of caregivers had consulta-
tions elsewhere before presenting to RVTH or Basse. The 
mean cost to families before hospitalisation in Basse was 
US$1.60 (95 % CI 1.1–2.1) and US$7.50 (95 % CI 5.6–9.3) 
at RVTH, p value < 0.001. The main modes of transport 
to the hospital were taxi and ambulance at both sites 
(Additional file 1: Table S8).
In the urban area more than 60 % of health facility vis-
its before hospitalisation occurred at health centres or 
other regional hospitals. In the rural setting, in addition 
to health centres, visits to traditional healers (15.3  %) 
and pharmacies (16.5  %) were common. In the urban 
area, the average cost for treatment at private clinics was 
US$19.00. In the rural area, the average cost of treatment 
from a traditional healer prior to admission was US$8.80 
(Additional file 1: Table S9).
Although the hospital provides meals for patients, fam-
ilies also bought food and received gifts from visitors dur-
ing the hospitalization period. Costs of meals provided 
by the hospital are incorporated in the bed day costs and 
are not included in the estimate of costs to the families 
during hospitalisation. The average out-of-pocket costs 
incurred before, during and after visits ranged from 
US$1.70 for OPD pneumonia at Basse to US$60 for inpa-
tient meningitis at RVTH (Table  3). The average after 
hospital costs highest for pneumococcal sepsis and men-
ingitis at RVTH, US$24.90 and US$16.50 respectively. 
The average burial costs for ten children at RVTH was 
US$ 32.80 (Median, IQR = 28.10, 25.70–40.0).
Family time lost
The total time lost by caregivers and visitors was esti-
mated for each patient as the time spent at the OPD and/
or at the ward. The average time lost by caregivers of 
Table 2 Provider hospital costs; patient specific and non-specific costs (bed day costs) US$
Los length of stay in hospital, IQR interquartile range
a  Ten died on the same day they were admitted, length of stay for these estimated as 1 day to cover nonspecific patient costs
b All drugs antibiotics and other non-essential drugs
c Others- intravenous fluids (IVF), blood transfusion, oxygen
d Subtotal all patient specific costs
e Non-specific costs such as cleaning, personnel
f Total costs patient specific cost plus bed day costs
Mean LOS 
daysa
Costs mean, median (IQR)
Patient specific costs Bed day costse Total costsf
All drugsb Investigations Othersc Subtotald
Basse
 Outpatient 
pneumonia 
n = 50
n/a 2.5, 1.3 (0.8–2.0) 3.0, 3.1 (1.9–5.0) n/a 5.5, 4.6 (3.2–5.9) n/a 5.5, 4.6 (3.2–5.9)
 Inpatient  
pneumonia 
n = 94
4.3 9.0, 5.2 (3.2–10.3) 28.2, 23.2 (21.1–26.5) 1.3, 0 (0–1.8) 39.0, 31.1 
(26.5–41.5)
21.8, 15.9 
(15.9–26.4)
60.9, 49.7 
(43.0–72.3)
 Sepsis n = 32 5.7 11.3, 5.5 (2.5–10.1) 48.8, 26.6 (23.2–73.0) 0.9, 0 (0–0) 61.0, 54.0 
(27.9–82.5)
24.9, 26.4 
(15.9–27.3)
90.9, 86.0 
(54.7–121.5)
 Bacterial  
meningitis 
n = 21
5.1 15.4, 6.6 (1.2–23.2) 85.2, 105.4 (69.9–
118.0)
3.4, 0.6 (0–2.34.0) 104.0, 113.2 
(71.1–131.5)
27.0, 26.4 
(5.3–43.3)
131.0, 123.7 
(112.3–169.2)
RVTH
 Outpatient 
pneumonia 
n = 50
n/a 3.2, 1.0 (0.5–2.4) 6.5, 5.4 (5.4–8.5) n/a 9.8, 7.8 (6.1–12.8) n/a 9.8, 7.8 (6.1–12.8)
 Inpatient  
pneumonia 
n = 81
7.8 16.8, 3.2 (1.8–7.8) 13.3, 8.5 (5.4–8.5) 3.6, 1.8 (0–5.4) 33.7, 15.3 
(10.3–29.4)
34.2, 26.2 
(17.5–35.0)
68.0, 43.5 
(30.7–71.8)
 Pneumococcal 
sepsis n = 4
5.0 9.1, 2.9 (1.1–17.0) 11.5, 6.9 (5.4–17.6) 9.2, 2.0 (0.8–17.6) 29.8, 34.8 
(18.4–41.2)
21.9, 10.9 
(9.4–39.3)
51.6, 39.2 
(29.3–74.0)
 Bacterial  
meningitis 
n = 8
6.6 43.3, 6.7 (3.2–37.7) 28.4, 11.9 (5.4–56.2) 3.5, 2.9 (0.8–6.5) 75.2, 54.8 
(16.2–98.6)
29.0, 21.8 
(13.1–37.1)
104.2, 85.4 
(35.9–120.5)
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hospitalized patients was 1.5 days in Basse and 5 days at 
RVTH. The majority of the time lost by family members 
was attributed to time spent by visitors, with an average 
of 4.5 and 11 h in total visitor time per patient at RVTH 
and Basse, respectively. The maximum number of visi-
tors/caregivers was 40 at RVTH and 28 at Basse. The esti-
mated loss of income per day ranged from US$22 for paid 
jobs to US$1 for those who would pay someone to look 
after their children at home while in hospital (Additional 
file  1: Table S10). The average estimated loss of income 
for time spent taking care of the sick child after discharge 
was US$8.10 [median, IQR 1.18, (0.18–4.15)]. Caregivers 
lost US$7.00 and visitors about US$1 on average per case.
Total costs associated with pneumococcal diseases
On average, provider costs for treating outpatient pneu-
monia, inpatient pneumonia, pneumococcal sepsis 
and bacterial meningitis were US$8, US$64, US$87 and 
US$124 per patient respectively. Including out-of-pocket 
costs, the costs from a societal perspective without con-
sidering productivity loss was US$14 and US$96 for 
pneumonia treated as an outpatient and inpatient respec-
tively, US$130 for pneumococcal sepsis and US$158 
for bacterial meningitis. The total societal costs due to 
outpatient pneumonia, inpatient pneumonia, pneu-
mococcal sepsis and meningitis increased to US$15, 
US$109, US$144 and US$170 per case respectively when 
family time loss was taken into account (Table 4).
Total costs associated with meningitis sequelae
A total of 70 children were identified for follow-up in the 
study of the economic burden of sequelae following men-
ingitis. Forty-seven (67 %) of these children were traced, 
eleven had died (23 % CFR) two had travelled out of the 
country, and two did not consent. In total, twenty-five 
children, 18 from Basse and 9 from RVTH were followed 
up.
The mean duration between the onset of meningi-
tis episodes and the interview was 27  months (includes 
time on admission and maximum 24  months after dis-
charge). The average age of the children was 34 months, 
(median, IQR 25, 14–38). The average cost to the families 
for taking care of the children during the acute phase was 
US$35.6; (US$21.30 in Basse and US$61.00 at RVTH). 
The average costs due to disability over the first 6 months 
period after discharge was US$26.0 and the average cost 
per patient (acute phase and disability) was US$62.5 
(Table 5). The disability of the children persists and may 
Table 3 Out-of-pocket costs before, during and after treatment by study site US$
IQR interquartile range
a Meals not provided by hospital for patient and care givers
b Estimate/actual cost of visitors gifts
c To and fro
d All costs incurred from up to 1 week after discharge from hospital, assumed transport cost home same as transport cost to the hospital, included in costs after 
hospital visit
e Before includes transport cost to the hospital
Beforee mean, 
median (IQR)
During mean, median (IQR) Afterd mean, 
median (IQR)
Total mean, median 
(IQR)
Mealsa Visitors giftb Visitors farec
Basse
 Outpatient pneu-
monia n = 50
1.7, 0 (0–1.8) 0.1, 0 n/a n/a n/a 0.8, 0 (0–1.5) 1.7, 0.02 (0–2.2)
 Inpatient pneumo-
nia n = 94
3.3, 1.5 (0–4.2) 5.1, 3.7 (1.7–7.0) 6.5, 4.7 (1.8–10.1) 5.2, 3.3 (1.1–7.3) 2.4, 1.1 (0–2.9) 20.0, 16.8 (9.9–25.0)
 Pneumococcal 
sepsis n = 32
4.9, 3.3 (0–7.6) 9.3, 9.3 (3.4–11.9) 22.3, 7.1 (1.5–10.0) 7.5, 5.3 (0–12.3) 2.3, 1.8 (0–3.9) 44.0, 28.6 (15.2–39.5)
 Bacterial meningitis 
n = 21
3.3, 3.3 (0–4.4) 9.0, 4.9 (0.9–11.6) 6.2, 3.7 (0–8.3) 5.7, 3.7 (0–9.2) 2.5, 1.8 (0–3.7) 30.8, 26.6 (5.3–45.4)
RVTH
 Outpatient pneu-
monia n = 50
9.6, 4.6 (2.0–11.0) 0.4, 0.02 (0–0.6) n/a n/a 1.9, 1.5 (0.7–2.1) 10.0, 4.8 (2.4–12.1)
 Inpatient pneumo-
nia n = 81
8.4, 4.1 (2.0–9.9) 6.6, 5.7 (2.9–8.5) 17.4, 14.1 (7.3–21.1) 12.3, 9.1 (4.–15.3) 4.2, 0.8 (0–3.1) 44.2, 40.6 (23.5–58.4)
 Pneumococcal 
sepsis n = 4
25.2, 21.5 (4.4–46.3) 3.5, 2.0 (0–7.0) 8.9, 5.2 (0–17.8) 2.9, 3.1 (0.6–5.3) 24.9, 16.1 (1.6–48.2) 40.6, 38.9 (4.7–66.4)
 Bacterial meningitis 
n = 8
10.9, 8.8 (2.3–14.9) 4.8, 4.4 (2.1–6.1) 26.4, 16.4 (6.8–41.7) 17.9, 11.6 (5.1–24.5) 16.5, 3.5 (0–34.7) 60.0, 57.2 (27.4–90.1)
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last a lifetime therefore projecting the costs the average 
will be about US$50 by the end of the year and US$2750 
over their entire life (median age, 3 years and life expec-
tancy 58 years).
Fifteen out of the twenty-seven (55.6 %) children exam-
ined had at least one form of neurological deficit (data 
not shown). On average, a child could not perform any 
of their usual activities for a period of 10  days (range 
1-90) after the onset of the episode of meningitis, and 
for 28  days (range 0–480  days) children could not per-
form some activities. Only three households had a fam-
ily member that was unable to work because of the need 
to care of the disabled child. The estimated mean loss 
of earnings per household was US$2.79 over 6  months 
which translates to an average of US$174 throughout the 
life of the child. On average, each household spent less 
than 1  day per month at health facilities providing care 
due to the child’s disability.
Sensitivity analysis
A sensitivity analysis was conducted based on varied uti-
lization of diagnostic tests at the two facilities. The first 
scenario was based on the rates of diagnostic testing at 
RVTH where only 2  % (2/93) of inpatients had a blood 
culture. We thus assumed that 2 % of inpatients in Basse 
had a blood culture. Under this scenario, the total cost 
for blood culture in Basse declined from US$2250 to 
US$50 (Table 6). There were no X-rays or blood culture 
for patients with pneumonia treated at outpatient from 
both study sites because cases are treated based on clini-
cal diagnosis. Therefore, the costs associated with X-rays 
and blood culture was zero for outpatient cases. In sce-
nario 2, the average cost per case for diagnostic tests in 
the MRC laboratory and private laboratories was similar, 
whereas the RVTH lab costs which are subsidized were 
lower (Table 6).
Discussion
In this study, we have filled an important evidence gap 
by estimating the costs of a range of pneumococcal 
diseases, from a societal perspective, in a typical sub-
Saharan Africa setting. We have included the costs to 
the health care provider, out-of-pocket costs incurred 
by families, productivity loss and also assessed the eco-
nomic burden associated with sequelae following bacte-
rial meningitis.
The provider costs associated with the treatment of 
pneumococcal diseases in the Gambia are substantial, 
ranging from US$5 for outpatient pneumonia to a peak 
of US$130 for hospitalized pneumonia patients in urban 
settings. Out-of-pocket costs to families are also high, 
with expenditure between $2 for children treated for 
pneumonia as outpatients and US$60 for children with 
meningitis.
The average provider costs for one case of outpatient 
pneumonia was US$8. Outpatient pneumonia is the most 
common of the disease categories and therefore despite 
the cost per case being relatively small, the overall cost to 
the provider is substantial. At RVTH, there are approxi-
mately 30 cases of outpatient pneumonia for each case of 
meningitis (median cost US$85), consequently the eco-
nomic burden due to outpatient pneumonia was more 
than five times that of meningitis. In the case of meningi-
tis, the average cost for treating one case was higher than 
that for inpatient pneumonia nevertheless, given that 
the number of pneumonia admissions is 15 times that of 
meningitis admission, the overall economic burden for 
pneumonia admissions was about ten times greater.
Similar to other African studies, meningitis was the most 
expensive condition to treat [6, 18]. In Kenya, the cost of 
Table 4 Average costs of pneumococcal diseases per patient (US$)
IQR inter quartile range, OOP out of pocket costs
Diagnosis Total costs by perspective [mean, (median, IQR)]
Provider Societal (includes family OOP) Societal (family time loss valued)
Outpatient pneumonia 7.6 (6.1, 4.1–8.3) 13.5 (8.6, 5.1–15.2) 15.4 (11.2, 6.4–18.3)
Inpatient pneumonia 64.0 (47.9, 38.2–72.3) 95.5 (79.3,58.9–115.5) 108.6 (87.0, 63.0–129.7)
Pneumococcal sepsis 86.6 (76.5, 50.1–118.8) 130.2 (102.2, 71.8–172.3) 143.7 (122.3, 74.3–193.6)
Bacterial meningitis 123.6 (121.6, (74.7–138.9) 157.6 (139.4, 117.6–198.2) 170.3 (150.1, 117.9–233.2)
Table 5 Average, median, (IQR) out-of-pocket costs 
to families of children with meningitis (US$)
IQR inter quartile range
a Costs before, after and up to 1 week after the acute episode
b Costs incurred as a result of disability
Costs Acutea Disabilityb Total
Basse 21.32, 12.4 (8.4–19.7) 12.0, 0 (0–7.5) 33.3, 15.2 (8.4–37.9)
RVTH 61.0, 33.3 (18.0–45.7) 53.2, 31.2 (12.9–39.3) 114.2, 66.5 
(30.9–85.0)
Total 35.6, 18.4 (9.9–37.5) 26.8, 7.2 (0–31.2) 62.5, 30.8 (9.9–66.9)
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meningitis treatment was estimated to be over $160 in a 
district hospital and over $200 in the central national hos-
pital [6]. Our findings estimated a somewhat lower cost for 
treatment of meningitis, which is likely due to differences 
in the available diagnostic tests, costs of resources, and 
admission policies in Kenya and The Gambia. Treatment 
costs of pneumonia at OPD derived from this study was 
also lower than that in Zambia [7]. Pneumonia treatment 
costs were greater at RVTH whereas treatment costs for 
sepsis and meningitis were higher in Basse. This may be 
explained in part by the length of stay, which was longer at 
RVTH than Basse for inpatients. For OPD pneumonia, the 
difference was due mainly to the cost of diagnostic tests.
The treatment protocol for pneumonia and meningitis 
was similar across all surveyed sites; outpatient pneu-
monia was treated with cotrimoxazole or amoxicillin, 
while meningitis was treated with benzyl penicillin and 
chloramphenicol. The availability of X-ray and microbi-
ology tests however varied between locations as did the 
provision of food for patients. The health facility sur-
vey showed however that national treatment guidelines 
for pneumonia and meningitis are used throughout the 
country, therefore our estimates for drug costs can be 
generalized within the country.
Studies in Colombia and India have shown differences 
in treatment costs at tertiary facilities compared to the 
secondary and primary level facilities [19, 20]. This may 
be due to a certain extent to cost of diagnostic tests 
which are routine in some secondary/tertiary hospitals 
in other developing countries. Because of the presence of 
the surveillance study in Basse we did not expect to see 
a difference between Basse and RVTH. We noted that 
blood cultures, analysis of cerebrospinal fluid and chest 
X-rays which are routinely conducted by the pneumococ-
cal disease surveillance system in Basse were not always 
available at RVTH.
We showed that provider costs represent 50 to 70  % 
of the societal costs. Out-of-pocket costs ranged from 
Table 6 Scenario analysis using different proportion and costs of diagnostic tests at the two facilities
RVTH N = 93 Basse N = 147
Scenario 1
X-ray
 Number of x-rays 59 (60) 118 (80)
 Total cost 18.3 365.8
Proportion who had a diagnostic test
 Assuming 60 % of inpatients at Basse had an x-ray – 273.4
 Assuming 80 % of inpatients at RVTH had an x-ray 231 –
Blood culture
 Number of blood culture 2 (2) 126 (85)
 Total cost 335 2252
 Cost based on percentage of inpatients at RVTH that had blood culture – 53
 Cost based on percentage of inpatients at Basse that had blood culture 1425 –
Scenario 2
Costs for diagnostic tests from MRC, RVTH or private laboratories
MRC lab costs
 Outpatient pneumonia 6.5, 5.4 (5.4–8.5) 2.98, 3.1 (1.9–5.0)
 Inpatient pneumonia 13.3, 8.5 (5.4–8.5) 28.2, 23.2 (21.1–26.5)
 Pneumococcal sepsis 11.5, 6.9 (5.4–17.6) 48.8, 26.6 (23.2–73.0)
 Bacterial meningitis 28.4, 11.9 (5.4–56.2) 85.2105.4 (69.9–118.0)
RVTH lab costs
 Outpatient pneumonia 1.28 (0.08, 0.08–3.18 1.63 (3.1, 0.04–3.1)
 Inpatient pneumonia 8.74 (3.18, 0.06–3.18) 15.80 (9.57,9.53–9.61)
 Pneumococcal sepsis 2.91 (1.63, 0.08–5.75) 35.5 (9.61, 7.41–59.57)
 Bacterial meningitis 21.30 (4.10, 0.08–51.9) 75.5 (100.08, 56.47–106.43)
Private lab costs
 Outpatient pneumonia 5.01, 3.68 (3.68–6.78) 2.64, 3.1 (1.84, 3.68)
 Inpatient pneumonia 11.95, 6.78 (3.78, 6.78) 21.57, 15.97 (14.13–17.81)
 Pneumococcal sepsis 8.45, 5.23 (3.68, 13.21) 41.08, 18.74 (14.71–65.94)
 Bacterial meningitis 26.05, 10.18 (3.68–54.60) 79.95, 103.65 (62.87, 111.03)
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one to ten times of the average daily household expenses 
(US$5 to US$9). Daily household expenses were higher in 
Basse where the household size was larger.
The findings of this report have a number of limita-
tions. We enrolled few cases of pneumococcal sepsis 
and bacterial meningitis. Sepsis cases were particularly 
low at RVTH reflecting the lack of reliable microbiol-
ogy services. We identified a total of 36 cases of pneu-
mococcal sepsis and the median costs for diagnostic 
tests were US$49 and US$12 at Basse and RVTH. Most 
of the pneumococcal sepsis cases occurred in children 
admitted with pneumonia, so it was not unexpected 
that the costs of these two conditions, inpatient pneu-
monia and sepsis were similar. We included all cases of 
bacterial meningitis identified during the study period. 
Of the 29 bacterial meningitis cases, the mean pro-
vider treatment costs ranged from US$104 to US$131. 
In general, antibiotic treatment duration for pneumo-
coccal meningitis is longer than for other bacteria [21]. 
The same first line antibiotics were used in treatment 
of meningitis throughout the country as seen from the 
health facility survey, again giving confidence that the 
treatment costs can be generalized across the country. 
Drugs for public health facilities are obtained from one 
central source.
The economic burden of pneumococcal diseases may 
be underestimated since we know that not all cases pre-
sent to health facilities [22]. A health utilization survey 
has been conducted in URR and data will be used to 
adjust for children who do not present to health facili-
ties in future analyses of cost effectiveness. Our data may 
also be extrapolated to estimate treatment costs in adults 
since the disease burden of pneumococcal diseases is 
greatest in the very young and the elderly [23], and the 
antibiotics used for treatment are similar. We expect a 
greater disease burden if disease in adults is taken into 
consideration. Cost-effectiveness analyses including 
adults may need to adjust for length of stay in hospital 
which may be longer in adults [24].
The study excluded some cost components, such as 
costs of buildings, equipment, maintenance, and utilities 
from the main analysis. We did not collect burial costs at 
Basse however, if we extrapolate the average burial cost 
for children at RVTH to Basse, the family out-of-pocket 
cost increases by another US$650.
Our difficulty in tracing children for follow-up after 
pneumococcal meningitis is likely to reflect the high 
mortality associated with this condition. Even though 
we confirmed 11 deaths, it is possible that more of the 
children not traced (23/70) had died. For those children 
that were followed up, the estimated monthly costs of 
providing care for the child was around US$3. For one 
in ten families, one family member was not able to work 
due to the need to provide special levels of care for the 
child.
Clearly, pneumococcal meningitis continues to be 
associated with substantial economic and social burdens 
for families, even when children survive the acute illness. 
Meningitis is such a dramatic event that mothers would 
remember details of their child’s illness but we cannot 
rule out recall bias. Mothers were to give costs at the 
time of the illness but it is possible that they stated cur-
rent costs rather than actual costs incurred at the time of 
the incidence resulting in overestimation of costs due to 
inflation over time.
Our findings demonstrate that pneumococcal dis-
ease in The Gambia is associated with substantial eco-
nomic costs of more than a US$100 for admitted cases. 
The health system meets 50 to 80 % of these costs. Out-
of-pocket costs were one to ten times the average daily 
household expenditure. Compared to Kenya and Paki-
stan, fewer costs were passed on to caregivers by the 
health system [6, 18]. These are timely data to support 
investments in prevention and treatment programmes, 
and will be used for cost-effectiveness analyses of the 
introduction of pneumococcal conjugate vaccine.
The ultimate aim of economic analysis is to improve and 
support decisions around allocation of health resources. 
Understanding the costs associated with treating pneu-
mococcal disease highlights the magnitude of the costs 
that can be averted when these diseases are prevented. 
The economic burden numbers presented in this analy-
sis are, in aggregate, smaller than are reported in similar 
analyses in other larger countries. However, the economic 
burden of childhood pneumococcal disease is significant 
both for households and for the country as a whole. From 
the household perspective, out-of-pocket costs ranged 
from one to ten times daily household expenditures. 
These costs can be dramatic for the economically disad-
vantaged. Likewise, the economic burden of one case of 
inpatient pneumonia (US$109) is much larger than The 
Gambia’s health expenditure per capita of US$29 [25]. 
These numbers only provide partial insight into the eco-
nomic burden of pneumococcal disease in The Gambia. 
Nonetheless, they demonstrate the challenges faced by 
households and the country as a whole in dealing with 
one of the leading causes of childhood mortality.
Conclusions
The economic burden of pneumococcal diseases in The 
Gambia is substantial. Apart from the significant costs to 
the health care providers, families of children with pneu-
mococcal diseases incur considerable expenses during 
the course of treating the sick child. The introduction of 
pneumococcal conjugate vaccine has the potential to sig-
nificantly reduce this economic burden.
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